NCT02468375CompletedPhase 4
A Multicenter Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Samsung Medical Center
- Enrollment
- 434
- Locations
- 1
- Primary Endpoint
- Treatment Satisfation Questionnaire
Study Overview
Brief Summary
The purpose of this study is to measure the treatment satisfaction after switching to mirabegron in patient with Overactive Bladder(OAB) who were unsatisfied with efficacy of antimuscarinic therapy or adverse event.
Patient will take the mirabegron 50mg/day for 12 weeks, and the satisfation of the therapy will be measured with Treatment Satisfaction Questionnaire(TSQ), Global Response Assessment(GRA), OAB-q short form, OAB Symptom Score and Willingness to continue Questions.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •<SCREENING>
- •over 20 years old, who has overactive bladder at least for 3 months.
- •total OABSS score over 3 points, and number 3 question score should be over 2 points.
- •if one of the criteria met,
- •efficacy : who are unsatisfied with antimuscarinics during the past 2 years. (should be treated at least 8 weeks) 2) adverse event(AE) : who are unsatisfied with antimuscarinics treatment due to AE(dry mouth, constipation, etc) 4.subject who can write voiding diary. 5.subject who can understand about the study and sign the informed concent form.
- •<BASELINE> Voiding Diary for 3 days
- •micturition 8/day
- •urgency 2/day
Exclusion Criteria
- •<SCREENING>
- •subject has history or risk of acute urinary retension.
- •subject has prostate cancer.
- •subject has lower urinary tract obstruction and judge by investigator that the subject is not appropriate to participate in this study.
- •subject has a previous or current bladder tumor.
- •subject has significant stress incontinence or mixed incontinence where stress is the dominant factor.
- •prohibitied, permitted medication. 6-
- •subject who has intake Alpha-blocker, Diabetes insipidus medication, PDE5 inhibitor(for BPH Tx), SSRI within 12weeks prior to Screening.
- •subject who has started, stopped or changed the dose of 5-Alpha Reductase Inhibitors(5-ARI) within 4 weeks prior to Screening.
- •Subject who currently intake Antimuscarinics, Antihistamines, Beta 2-adrenoreceptor agonist, loop diuretics,CYP2D6 substrates with narrow therapeutic index, CYP3A4 inducing agent, CYP 3A4 inhibitor, Antifungal agent, Antiarrythmic drugs.
- •subject who has Non-drug treatment including bladder training, pelvic floor muscle training within 12 weeks prior to Screening.
- •subject has severe hypertension which is defined as a sitting average systolic blood pressure over 180 mmHg, and/or diastolic blood pressure over 11 0mmHg.
- •pulse over 100 bpm or below 50 bpm.
- •subject has an indwelling catheter or practices intermittent self-catheterization.
- •subject who had surgery which can influence urinary track function (ex, TURP, Laser treatment,etc.).
- •subject who had complication of urinary tract infection, urinary stone, interstitial cystitis, or recurrent UTI history.
- •subject has known or suspected hypersensitivity to Beta 3 adrenalin receptor agonist.
- •subject has clinically significant cardiovascular diseases hepatic diseases renal diseases immunization diseases lung diseases and cancer.
- •subject who has planed pregnency, breast feeding during clinical trial period.
- •<BASELINE> voiding volume over 3000ml per day. post voiding residual volume over 200ml
Arms & Interventions
mirabegron 50mg
Experimental
about 434 OAB patients intake mirabegrone 50mg/day for 12 weeks.
Intervention: mirabegron 50mg (Drug)
Outcomes
Primary Outcomes
Treatment Satisfation Questionnaire
Time Frame: at the end of the treatment( 12weeks)
Secondary Outcomes
- urgency change(4weeks, 12weeks)
- OABq-SF score change(4weeks, 12weeks)
- micturtion change(4weeks, 12weeks)
- incontinence change(4weeks. 12weeks)
- Willingness to continue Questions(12 weeks)
- OABSS score change(4weeks, 12weeks)
- Global Response Assessment(GRA) score change(4weeks, 12weeks)
Investigators
KYU-SUNG LEE
professor
Samsung Medical Center
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)Overactive BladderNCT02656173Astellas Pharma Inc568
Completed
Phase 4
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangeRelapsing Remitting Multiple SclerosisNCT01317004Novartis Pharmaceuticals61
Completed
Phase 4
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)Overactive BladderBenign Prostatic HyperplasiaNCT02757768Astellas Pharma Global Development, Inc.715
Completed
Not Applicable
Follow-up Study on Recipients of Treatment at the Jerusalem Center for the Treatment of PsychotraumaHealthyNCT00463138Herzog Hospital100
Completed
Phase 4
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)Overactive Bladder (OAB)NCT02216214Astellas Pharma Global Development, Inc.888